Athena Pharmaceutiques Oral Dispersible Tablets

Athena Pharmaceutiques Oral Dispersible Tablets

X

Find Clinical Drug Pipeline Developments & Deals by Delpor

Delpor
Developments
Full Screen View

Delpor

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

No Presentations

VIDEO(s)

No Video

DIGITAL CONTENT

1 News

1 News

DEVELOPMENTS

2 Drug(s) in Development

2 Drug(s) in Development

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Delpor

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Delpor Announces First Subjects Dosed in Phase 1 Clinical Trial of Once or Twice-Yearly Naltrexone Implant for Opioid Addiction

Details:

If approved, DLP-160 (6-12 month Naltrexone Implant) is expected to offer a major advancement in the treatment of opioid use disorder by improving medication adherence and reducing relapses.

Lead Product(s): Naltrexone

Therapeutic Area: Psychiatry/Psychology Product Name: DLP-160

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 29, 2022

ASK
US

Upload
your Pipeline Activity

Delpor

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Delpor Advances Pipeline to Include Spasticity Maintenance Therapy with $2.5 Million NIH Grant for Tizanidine Implant

Details:

Proceeds from the financing will be used for the advancement of the company’s tizanidine implant product (DLP-208) for moderate-severe spasticity. DLP-208 can provide sustained therapy for several months, while only requiring a 10-minute procedure in an outpatient setting.

Lead Product(s): Tizanidine HCl

Therapeutic Area: Musculoskeletal Product Name: DLP-208

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: National Institutes of Health

Deal Size: $2.5 million Upfront Cash: Undisclosed

Deal Type: Funding November 16, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY